Today, Batavia Biosciences announces the expansion of its process development facilities in Woburn, MA, United States to accommodate the increasing market demand for viral vectors.
Chris Yallop, COO at Batavia Biosciences, explains: “Advances in immuno-oncology, infectious diseases and gene therapy have given rise to a profound increase in the global demand for process development and clinical manufacturing of viral vector based products.”
The R&D facility in Woburn, located just north of Cambridge (MA) allows Batavia Biosciences to expand its process development capacity for its HIP-Vax® platform. Through innovative bioprocess intensification, HIP-Vax technology allows clinical manufacturing at a lab-scale. The highly intensified production processes developed by Batavia, have significantly lower cost-of-goods compared to traditional production platforms.
Menzo Havenga, CEO at Batavia Biosciences, adds: “Especially in the field of virotherapy, current low production yields force developers to a use relatively large scale equipment even to support phase 1 and 2 clinical trials. Our HIP-Vax technology platform provides a rapid and cost-effective alternative, providing a scalable and robust process using a bench-scale manufacturing footprint.”
The newly added R&D spaces are fully equipped to provide production, purification and analytical support for diverse viral vectors including lentiviral and AAV vectors.
Ingrid van Aarle, HR manager at Batavia Biosciences, says: “We are always on the lookout for new talent, especially with the new infrastructure coming online soon. Scientists and technicians, who wish to contribute to making potential life-saving biopharmaceuticals more affordable and better available and want to develop their careers in the exciting world of viral vectors, are invited to apply via Batavia’s jobs page.”
Menzo concludes: “At Batavia Biosciences, we are aware every day that the patient is waiting. With the completion of this build-out, we are well positioned to maintain speed and quality of bringing candidate biopharmaceuticals from the bench to the clinic.”